Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;12(3):163-168.
doi: 10.5114/pg.2017.70467. Epub 2017 Sep 30.

Systemic sclerosis and the gastrointestinal tract

Affiliations
Review

Systemic sclerosis and the gastrointestinal tract

Irena Walecka. Prz Gastroenterol. 2017.

Abstract

Systemic sclerosis (SSc) is an autoimmunological disease of unknown origin with complex pathogenesis and multiple organ involvement. It is characterised by vascular and immunological abnormalities leading to fibrosis of the skin and internal organs. It is a rather rare disease with a prevalence of around 20 per 100,000. The disease results in heterogeneous clinical findings and different courses. Systemic sclerosis usually begins with the onset of Raynaud's phenomenon (RP), followed by skin sclerosis and internal organ involvement, although it may appear synchronously with RP. Gastrointestinal involvement is a serious and prevalent complication of SSc, and the oesophagus is the most frequently affected organ. Both limited and diffuse cutaneous SSc involve internal organs, with the involvement of the gastrointestinal tract as a leading cause of morbidity. At present, treatment is mainly symptomatic with no disease-modifying drugs.

Keywords: autoantibodies; gastrointestinal involvement; systemic sclerosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Raynaud’s phenomenon in a patient with SSc
Figure 2
Figure 2
Patient with skin sclerosis and telangiectasias
Figure 3
Figure 3
Digital ulcers and necrosis in patient with systemic sclerosis
Figure 4
Figure 4
Dilation of oesophagus in a patient with systemic sclerosis
Figure 5
Figure 5
Dilation of oesophagus in a patient with systemic sclerosis

Similar articles

Cited by

References

    1. Szymanska E, Wieczorek M, Lagun Z. Vascular changes in autoimmunological connective tissue diseases. Acta Angiol. 2016;22:172–6.
    1. Sticherling M. Systemic sclerosis – dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. Prof. Dr. Jan C. Simon, Leipzig (eds) JDDG. 2012;10:705–16. - PubMed
    1. Manetti M, Matucii-Cerinic M. The new frontier in systemic sclerosis: from epigenetics to new treatments. Rheumatology. 2015;54:1757–8. - PubMed
    1. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340–54. - PubMed
    1. Sobanski V, Dauchet L, Lefèvre G, et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis: prevalence of anti-RNAP III in SSc. Arthritis Rheumatol. 2014;66:407–17. - PubMed

LinkOut - more resources